High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)
Primary Purpose
Post-Traumatic Stress Disorder
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)
Sponsored by
About this trial
This is an interventional treatment trial for Post-Traumatic Stress Disorder
Eligibility Criteria
Inclusion Criteria:
- Signed Patient Information and Consent.
- Patients with primary Post-Traumatic Stress Disorder (as diagnosed by MINI) and DSM IV TR.
- Patients with CAPS score of at least 40.
- Males or females between 18-65 years of age.
- Patients not taking PTSD pharmacotherapy for at least last 2 weeks prior to commencing in the study or if they are taking PTSD pharmacotherapy it must be stable for at least 6 weeks prior to the start and not be changed during the 6 weeks of the study treatment phase.
- Individual or group supportive psychotherapy may continue during the study but will not be allowed to start new psychotherapy during the 6 weeks of the study treatment phase.
Exclusion Criteria:
- Current primary Axis I disorder including Schizophrenia, Bipolar Disorder type I, Major Depressive Disorder.
- Other primary Axis I disorders which, in the opinion of the investigator, may affect the outcome of this study.
- Patients with HDRS score ≥ 18.
- A metallic implant in cranium (except the mouth).
- Patients with severe or unstable medical conditions, which in the opinion of the investigator would interfere with their progress or safety.
- ECT treatment within the last three months.
- Patients with a history of epilepsy.
- Patients with neurological disorder leading to increased intracranial pressure.
- Patients with severe cardiac disorder or intracardiac lines and pacemakers.
- Patients with current suicide risk ≥ 6 points by MINI.
Sites / Locations
- Dr. Dancho Dilkov
- Providence Care Mental Health Services
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Active rTMS
2
Arm Description
Repetitive Transcranial Magnetic Stimulation
Device: Sham (placebo)
Outcomes
Primary Outcome Measures
Clinician Administered PTSD Scale (CAPS) in both active and sham groups
Secondary Outcome Measures
Treatment Outcome PTSD scale (TOP-8)
Hamilton Anxiety Scale
Hamilton Depression Rating Scale
Clinical Global Impression Scale (both severity and improvement)
Social Functioning-36 Quality of Life Scale version(1)
Pittsburgh Sleep Quality Index
PTSD Checklist-civilian (PCL-C)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00685152
Brief Title
High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)
Official Title
High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Queen's University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of high-frequency (20Hz) rTMS applied to the right dorsolateral prefrontal cortex for 6 weeks. The primary objective is to evaluate the change in PTSD symptoms before and after six weeks of high-frequency rTMS treatment as measured by the Clinician Administered PTSD Scale (CAPS) in both active and control groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-Traumatic Stress Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active rTMS
Arm Type
Experimental
Arm Description
Repetitive Transcranial Magnetic Stimulation
Arm Title
2
Arm Type
Sham Comparator
Arm Description
Device: Sham (placebo)
Intervention Type
Device
Intervention Name(s)
Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)
Other Intervention Name(s)
rTMS machine (MagPro, Medtronic).
Intervention Description
6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
Primary Outcome Measure Information:
Title
Clinician Administered PTSD Scale (CAPS) in both active and sham groups
Time Frame
pre, week 2,4,6,8 & 12
Secondary Outcome Measure Information:
Title
Treatment Outcome PTSD scale (TOP-8)
Time Frame
Pre, week 2,4,6,8 & 12
Title
Hamilton Anxiety Scale
Time Frame
Pre, week 2,4,6,8 & 12
Title
Hamilton Depression Rating Scale
Time Frame
Pre, week 2,4,6,8 & 12
Title
Clinical Global Impression Scale (both severity and improvement)
Time Frame
Pre, week 2,4,6,8 & 12
Title
Social Functioning-36 Quality of Life Scale version(1)
Time Frame
Pre, week 2,4,6,8 & 12
Title
Pittsburgh Sleep Quality Index
Time Frame
Pre, week 2,4,6,8 & 12
Title
PTSD Checklist-civilian (PCL-C)
Time Frame
Pre, week 2,4,6,8 & 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed Patient Information and Consent.
Patients with primary Post-Traumatic Stress Disorder (as diagnosed by MINI) and DSM IV TR.
Patients with CAPS score of at least 40.
Males or females between 18-65 years of age.
Patients not taking PTSD pharmacotherapy for at least last 2 weeks prior to commencing in the study or if they are taking PTSD pharmacotherapy it must be stable for at least 6 weeks prior to the start and not be changed during the 6 weeks of the study treatment phase.
Individual or group supportive psychotherapy may continue during the study but will not be allowed to start new psychotherapy during the 6 weeks of the study treatment phase.
Exclusion Criteria:
Current primary Axis I disorder including Schizophrenia, Bipolar Disorder type I, Major Depressive Disorder.
Other primary Axis I disorders which, in the opinion of the investigator, may affect the outcome of this study.
Patients with HDRS score ≥ 18.
A metallic implant in cranium (except the mouth).
Patients with severe or unstable medical conditions, which in the opinion of the investigator would interfere with their progress or safety.
ECT treatment within the last three months.
Patients with a history of epilepsy.
Patients with neurological disorder leading to increased intracranial pressure.
Patients with severe cardiac disorder or intracardiac lines and pacemakers.
Patients with current suicide risk ≥ 6 points by MINI.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roumen Milev, MD
Organizational Affiliation
Queen's University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dr. Dancho Dilkov
City
Sofia
Country
Bulgaria
Facility Name
Providence Care Mental Health Services
City
Kingston
State/Province
Ontario
ZIP/Postal Code
K7L 4X3
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)
We'll reach out to this number within 24 hrs